KLK3 and prostate cancer: The combined use of FR + CTCs and PSA further increased diagnostic efficiency (FR + CTCs, 0.912; total PSA, 0.857), suggesting that FORα could serve as a valuable early diagnostic marker in prostate cancer, especially for patients with uncertain PSA levels21.